Marian M. Humphries

Marian M. Humphries

Auto-generated profile, based on publicly available information

Marian M. Humphries

Trinity College Dublin

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in Genes
Verified
Journal Article
Open access
PDF file
AKAnna-Sophia Kiang
Anna-Sophia Kiang
PKPaul F. Kenna
Paul F. Kenna
MHMarian M. Humphries
Marian M. Humphries
EOEma Ozaki
Ema Ozaki
RKRobert Koenekoop
Robert Koenekoop
PHPete Humphries
Pete Humphries
RPE65 isomerase, expressed in the retinal pigmented epithelium (RPE), is an enzymatic component of the retinoid cycle, converting all-trans retinyl ester into 11-cis retinol, and it is essential for vision, because it replenishes the photon capturing 11-cis retinal. To date, almost 200 loss-of-function mutations have been identified within the RPE65 gene causing inherited retinal dystrophies, most notably Leber congenital amaurosis (LCA) and autosomal recessive retinitis pigmentosa (arRP), which are both severe and early onset disease entities. We previously reported a mutation, D477G, co-segregating with the disease in a late-onset form of autosomal dominant RP (adRP) with choroidal involvement; uniquely, it is the only RPE65 variant to be described with a dominant component. Families or individuals with this variant have been encountered in five countries, and a number of subsequent studies have been reported in which the molecular biological and physiological properties of the variant have been studied in further detail, including observations of possible novel functions in addition to reduced RPE65 enzymatic activity. With regard to the latter, a human phase 1b proof-of-concept study has recently been reported in which aspects of remaining vision were improved for up to one year in four of five patients with advanced disease receiving a single one-week oral dose of 9-cis retinaldehyde, which is the first report showing efficacy and safety of an oral therapy for a dominant form of RP. Here, we review data accrued from published studies investigating molecular mechanisms of this unique variant and include hitherto unpublished material on the clinical spectrum of disease encountered in patients with the D477G variant, which, in many cases bears striking similarities to choroideremia.

24 August 2011 in European Journal of Human Genetics
Verified
Journal Article
Closed access
MHMarian M Humphries
Marian M Humphries
PKPaul F Kenna
Paul F Kenna
MCMatthew Campbell
Matthew Campbell
LTLawrence C S Tam
Lawrence C S Tam
ANAnh T H Nguyen
Anh T H Nguyen
PHPeter Humphries
Peter Humphries

Verified
Journal Article
Open access
PDF file
SMSophia Millington-Ward
Sophia Millington-Ward
Naomi ChaddertonNaomi Chadderton
Naomi Chadderton
Laura Katharine FinneganLaura Katharine Finnegan
Laura Katharine Finnegan
IPIris J. M. Post
Iris J. M. Post
MCMatthew Carrigan
Matthew Carrigan
GFG. Jane Farrar
G. Jane Farrar
Age-related macular degeneration (AMD) is the most common cause of blindness in the aged population. However, to date there is no effective treatment for the dry form of the disease, representing 85–90% of cases. AMD is an immensely complex disease which affects, amongst others, both retinal pigment epithelium (RPE) and photoreceptor cells and leads to the progressive loss of central vision. Mitochondrial dysfunction in both RPE and photoreceptor cells is emerging as a key player in the disease. There are indications that during disease progression, the RPE is first impaired and RPE dysfunction in turn leads to subsequent photoreceptor cell degeneration; however, the exact sequence of events has not as yet been fully determined. We recently showed that AAV delivery of an optimised NADH-ubiquinone oxidoreductase (NDI1) gene, a nuclear-encoded complex 1 equivalent from S. cerevisiae, expressed from a general promoter, provided robust benefit in a variety of murine and cellular models of dry AMD; this was the first study employing a gene therapy to directly boost mitochondrial function, providing functional benefit in vivo. However, use of a restricted RPE-specific promoter to drive expression of the gene therapy enables exploration of the optimal target retinal cell type for dry AMD therapies. Furthermore, such restricted transgene expression could reduce potential off-target effects, possibly improving the safety profile of the therapy. Therefore, in the current study, we interrogate whether expression of the gene therapy from the RPE-specific promoter, Vitelliform macular dystrophy 2 (VMD2), might be sufficient to rescue dry AMD models.

4 August 2012
Verified
Book Chapter
Closed access
PDF file
PHPete Humphries
Pete Humphries
MHMarian M. Humphries
Marian M. Humphries
LTLawrence C. S. Tam
Lawrence C. S. Tam
GFGwyneth Jane Farrar
Gwyneth Jane Farrar
PKPaul Kenna
Paul Kenna
AKAnna-Sophia Kiang
Anna-Sophia Kiang


4 August 2012
Verified
Book Chapter
Closed access
PDF file
PHPete Humphries
Pete Humphries
MHMarian M. Humphries
Marian M. Humphries
LTLawrence C. S. Tam
Lawrence C. S. Tam
GFG. Jane Farrar
G. Jane Farrar
PKPaul F. Kenna
Paul F. Kenna
AKAnna-Sophia Kiang
Anna-Sophia Kiang